natgillin/translations-raw huggingface dataset:
Sore throat or mouth has been reported with nebulised colistimethate sodium and may occur with Colobreathe. 
Prilikom primjene nebuliziranog kolistimetatnatrija prijavljena je grlobolja ili bol u ustima, pa se mogu pojaviti i s lijekom Colobreathe.
Each 56 capsule pack contains one Turbospin powder inhaler device and 7 blisters of 8 capsules or one Turbospin powder inhaler device and 4 blisters of 14 capsules (56 hard capsules) sufficient for 4 weeks use. 
Svako pakiranje od 56 kapsula sadrži jedan inhalator za prašak Turbospin i 7 blistera sa 8 kapsula ili 4 blistera sa 14 kapsula (56 tvrdih kapsula), što je dovoljno za 4 tjedna primjene.
What you need to know before you use Colobreathe Do not use Colobreathe: 
Što morate znati prije nego počnete primjenjivati Colobreathe
Of these, 187 patients aged 6 years and above were exposed to Colobreathe one capsule twice daily in a 24-week, phase 3 comparative study. 
izloženo jednoj kapsuli lijeka Colobreathe dvaput dnevno u 24-tjednom komparativnom ispitivanju faze III.
• Changes in how your lungs function (found by testing) 
• promjene u radu pluća (ustanove se pretragama)
Explanation of the Turbospin and how it works. 
Turbospin i njegovog rada.
• 8 hard capsules and one Turbospin inhaler device sufficient for 4 days use. 
• 8 tvrdih kapsula i jedan inhalator za prašak Turbospin, što je dovoljno za 4 dana primjene.
The Physician and patient “DVDs/leaflet forms” should contain the following key elements and messages: 
• Podatke „DVD za bolesnika“ u „obliku uputa" za bolesnike koji nemaju pristup čitaču DVD-a „DVD/podaci u obliku uputa“ za liječnike i bolesnike moraju sadržati sljedeće glavne stavke i poruke:
Clean the Turbospin inhaler after each dose using the following procedure: 1. 
Čišćenje inhalatora Turbospin Inhalator Turbospin očistite nakon svake doze na sljedeći način:
If you/your child are taking other treatments for cystic fibrosis you/your child should take them in the following order: 
Redoslijed kojim se moraju uzimati ili izvoditi drugi oblici liječenja Ako Vi/Vaše dijete liječite cističnu fibrozu još na koji način, redoslijed liječenja za Vas/Vaše dijete je sljedeći:
• Coughing up blood, wheezing, chest discomfort, asthma, productive cough (a cough which brings up mucus), infection of the lungs, lung crackles (your doctor would hear this when listening to your lungs using a stethoscope) 
(kašalj kojim se iskašljava sluz), plućna infekcija, pucketanja na plućima (čuje ih Vaš liječnik kada sluša pluća stetoskopom)
Preparing the Turbospin 
Priprema inhalatora Turbospin
It is possible while using Colobreathe that you may experience dizziness, confusion or have problems with your sight. 
Prilikom primjene lijeka Colobreathe može se pojaviti omaglica, smetenost, ili poteškoće s vidom.
The rinse should not be swallowed. 
Voda od ispiranja ne smije se progutati.
• The capsule is now pierced and the contents can be inhaled. 
• Time probijate kapsulu, što omogućuje udisanje njenog sadržaja.
For use with the Turbospin inhaler only. 
Samo za primjenu uz inhalator Turbospin.
Taking Colobreathe using the Turbospin inhaler Preparing the Turbospin 
Uzimanje lijeka Colobreathe koristeći inhalator Turbospin Priprema inhalatora Turbospin
How to use Colobreathe 
Kako primjenjivati lijek Colobreathe
Acute respiratory exacerbation 
Akutna respiratorna egzacerbacija
Colobreathe is inhaled into the lungs as a powder from the capsule using the hand-held inhaler called the Turbospin. 
Način primjene Colobreathe se u obliku praška iz kapsule udiše u pluća pomoću ručnog inhalatora, koji se naziva
Each capsule contains 1,662,500 IU, which is approximately equal to 125 mg of colistimethate sodium. 
Jedna kapsula sadrži 1 662 500 IU, što je približno jednako 125 mg kolistimetatnatrija.
Colobreathe capsules are to be used only with the Turbospin powder inhaler. 
Colobreathe kapsule smiju se primjenjivati samo uz pomoć Turbospin inhalatora za prašak.
Taking Colobreathe using the Turbospin inhaler 
Uzimanje lijeka Colobreathe koristeći inhalator Turbospin
• Chest physiotherapy 
• Respiratorna fizioterapija
player 
Serija
• blood in your sputum (the substance you cough up) 
• krv u ispljuvku (iskašljaju)
Package leaflet: Information for the user Colobreathe 1,662,500 IU inhalation powder, hard capsules 
Uputa o lijeku: Informacije za korisnika Colobreathe 1 662 500 IU prašak inhalata, tvrde kapsule kolistimetatnatrij
All patients using LOCF 
Forward, LOCF)
If other treatments are being taken, they should be taken in the following order: Inhaled bronchodilators 
U slučaju primjene drugih istodobnih liječenja, terapije se moraju se provoditi sljedećim redoslijedom:
Each capsule contains 1,662,500 IU (approximately equivalent to 125 mg) of colistimethate sodium. 
Jedna kapsula sadrži 1 662 500 IU (približno jednako 125 mg) kolistimetatnatrija.
Each capsule contains 1,662,500 IU (approximately equal to 125 mg) of colistimethate sodium 
Jedna kapsula sadrži 1 662 500 IU (približno jednako 125 mg) kolistimetatnatrija
Overdose can also cause acute renal failure characterised by decreased urine output and increased serum concentrations of BUN and creatinine. 
karakterizirano smanjenim izlučivanjem mokraće i povećanim koncentracijama BUN-a i keratinina u serumu.
• Weight fluctuations, decreased appetite 
• oscilacije težine, smanjeni apetit • tjeskoba
Actavis Group PTC ehf. 
Actavis Ltd.
Other possible side effects 
Duge moguće nuspojave
The Turbospin device should be discarded after completion of the treatment pack. 
Inhalator Turbospin valja zbrinuti kada se iskoristi sav lijek u pakiranju.
Polyethylene glycol Purified water Sodium lauryl sulfate 
Sastojci PEG-želatinskih tvrdih kapsula: želatina polietilenglikol pročišćena voda natrijev laurilsulfat
Pyrexia, asthenia, fatigue 
Pireksija, astenija, umor
Colobreathe 1,662,500 IU inhalation powder, hard capsules 
Colobreathe 1 662 500 IU prašak inhalata, tvrde kapsule
Bronchospasm or coughing may occur on inhalation. 
Prilikom inhaliranja može doći do bronhospazma ili kašljanja.
Colobreathe capsules should only be administered using the Turbospin inhaler device. 
Kapsule Colobreathe smiju se primjenjivati samo pomoću inhalatora Turbospin.
When you/your child start using Colobreathe, you/your child may find they have cough, breathlessness, tightness of chest or wheezing. 
Kada Vi/Vaše dijete započnete primjenjivati Colobreathe, može se dogoditi da se razvije kašalj,
Unscrew the mouthpiece, exposing the chamber of the Turbospin inhaler. 
Odvijte nastavak za usta, otkriva se komorica inhalatora Turbospin.
Keep this medicine out of the sight and reach of children. 
Kako čuvati Colobreathe Lijek čuvajte izvan pogleda i dohvata djece.
The active substance is colistimethate sodium. 
Djelatna tvar je kolistimetatnatrij.
Ear congestion 
Kongestija uha
• Nose bleeds, catarrh (mucus in your nose, which may make you feel blocked up), 
• krvarenje iz nosa, katar (sluz u nosu, zbog koje osjećate da je začepljen), iskašljavanje guste zelene sluzi, bol u grlu i sinusima
patients 
FARMACEUTSKI
High concentrations of total free colistin (mean 23.5mg/L) and total colistimethate (mean 178mg/L) were observed in sputum at 1 hour post-dose on Day 8 following BID dosing for 7 days across all age groups. 
Visoke koncentracije ukupnog slobodnog kolistina (prosjek 23,5 mg/l) i ukupnog kolistimetata (prosjek
Colobreathe 1,662,500 IU inhalation powder colistimethate sodium 
Colobreathe 1 662 500 IU prašak inhalata kolistimetatnatrij
Discard the Turbospin inhaler after the completion of a treatment pack. 
Inhalator Turbospin bacite kada iskoristite sav lijek u pakiranju.
Completed 
Zatvarač
Colobreathe 1,662,500 IU inhalation powder, hard capsules colistimethate sodium 
Colobreathe 1 662 500 IU prašak inhalata, tvrde kapsule kolistimetatnatrij
If you/your child needs to have other forms of colistimethate either by injection or nebulisation caution should be used but your doctor should be aware of this. 
Ako Vi/Vaše dijete trebate primiti druge oblike kolistimetata, bilo u obliku injekcije ili nebulizacijom,
Chest pain, dyspnoea exacerbated, pharyngolaryngeal pain, epistaxis, sputum purulent, abnormal chest sound, increased upper airway secretion 
Bol u prsištu, egzacerbacija dispneje, bol u ždrijelu i grkljanu, epistaksa, gnojni sputum,
• if you/your child need to have a general anaesthetic caution must be taken. 
• ako Vi/Vaše dijete uzimate kolistimetat u obliku injekcije ili nebulizacijom nužan je oprez; • ako se Vi/Vaše dijete trebate podvrgnuti općoj anesteziji, nužan je oprez.
Check with your doctor if you/your child are not sure. 
Ako Vi/Vaše dijete niste sigurni, posavjetujte se sa svojim liječnikom.
• Allergic (hypersensitivity) reactions, the signs may include rash and itching 
Manje često: mogu se javiti u manje od 1 na 100 osoba • alergijske reakcije (reakcije preosjetljivost), znakovi mogu uključivati osip i svrbež
Colistimethate sodium is converted to the base in vivo. 
Biotransformacija Kolistimetatnatrij se in vivo pretvara u kolistin.
Balance disorder, headache 
Poremećaj ravnoteže,
Screw the mouthpiece firmly back into place, put the cap back on and the inhaler is ready to be used for your next dose. 
Nastavak za usta čvrsto zavijte natrag na mjesto i vratite zatvarač.
• Shortness of breath 
• bol u prsnom košu • nedostatak zraka
Gastrointestinal disorders 
Inhalacijski bronhodilatatori
One capsule to be inhaled twice daily. 
Odrasli i djeca u dobi od 6 godina ili starija Dvaput dnevno inhalirati po jednu kapsulu.
• Chest pain 
• napadaji • pospanost
Vpriv velaglucerase alfa 
Vpriv velagluceraza alfa
This summary was last updated in 06-2016. 
Ovaj sažetak je posljednji put ažuriran u 06. 2016.
The main measure of effectiveness was the improvement in anaemia, one of the symptoms of the disease, after 41 weeks. 
Glavna mjera učinkovitosti bilo je poboljšanje anemije, jednog od simptoma bolesti, nakon 41 tjedna.
The first three infusions are given in hospital, but subsequent infusions may be given at home in patients who tolerate the medicine well. 
Prve tri infuzije primjenjuju se u bolnici, ali se naknadne infuzije mogu primijeniti kod kuće u onih bolesnika koji dobro podnose lijek.
The dose can be adjusted according to each patient's symptoms and response to treatment. 
Doza se može prilagoditi u skladu sa simptomima i reakcijom na liječenje svakog pacijenta zasebno.
Vpriv increased the amount of haemoglobin (the protein in red blood cells that carries oxygen) by an average of 1.6 grams per decilitre (from 11.4 g/dl) while imiglucerase increased the amount of haemoglobin by an average of 1.5 g/dl (from 10.6 g/dl). 
Vpriv je povećao količinu hemoglobina (proteina u crvenim krvnim stanicama koji prenosi kisik) za prosječno 1,6 grama po decilitru (od 11,4 g/dl), dok je imigluceraza povećala količinu hemoglobina za prosječno 1,5 g/dl (od 10,6 g/dl).
What measures are being taken to ensure the safe and effective use of Vpriv? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Vpriv?
The European Commission granted a marketing authorisation valid throughout the European Union for Vpriv on 26 August 2010. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Vpriv na snazi u Europskoj uniji od 26. kolovoza 2010.
Why has Vpriv been approved? 
Zašto je Vpriv odobren?
It is available as a powder that is made up into a solution for infusion (drip) into a vein. 
Dostupan je kao prašak koji se koristi za pripremu otopine za infuziju (drip u venu).
The recommended dose of Vpriv is 60 units/kg bodyweight, which is given as a one-hour infusion once every two weeks. 
Preporučena doza lijeka Vpriv je 60 jedinica/kg tjelesne težine koja se primjenjuje kao jednosatna infuzija svaka dva tjedna.
Vpriv must not be used in people who have a severe allergic reaction to velaglucerase alfa or any of the other ingredients. 
Vpriv se ne smije upotrebljavati u osoba koje imaju teške alergijske reakcije na velaglucerazu alfa ili bilo koji drugi sastojak.
Vpriv was as effective as imiglucerase at reducing anaemia. 
Vpriv je bio učinkovit kao i imigluceraza pri smanjenju anemije.
Home infusions should be supervised by a healthcare professional trained in emergency measures. 
Infuzije kod kuće trebao bi nadgledati zdravstveni djelatnik uvježban u primjeni hitnih mjera.
Other information about Vpriv 
Ostale informacije o lijeku Vpriv
The full EPAR for Vpriv can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Vpriv nalazi se na internetskim stranicama Agencije: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Velaglucerase alfa replaces the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it building up in the body. 
Velagluceraza alfa zamjenjuje enzim koji nedostaje u slučaju Glaucherove bolesti, pomažući pri razgradnji glukocerebrozida te pri zaustavljanju njegova nakupljanja u tijelu.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Vpriv.
The study also looked at control of other signs of the disease such as the increase in the number of platelets in the blood, and the reduction of the size of the liver and spleen. 
Ispitivanjem je obuhvaćena i kontrola drugih znakova bolesti, kao što je broj trombocita u krvi te smanjenje veličine jetre i slezene.
This document is a summary of the European public assessment report (EPAR) for Vpriv. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Vpriv.
In one main study involving 35 patients (including 9 children) with type 1 Gaucher disease, Vpriv was compared with imiglucerase (another medicine for Gaucher disease). 
Vpriv je u okviru jednoga glavnog ispitivanja, u kojem je sudjelovalo 35 bolesnika (uključujući devetero djece) s Gaucherovom bolesti tipa 1, uspoređen s imiglucerazom (drugim lijekom za Gaucherovu bolest).
Because the number of patients with Gaucher disease is low, the disease is considered ‘rare', and Vpriv was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 June 2010. 
Budući da je broj bolesnika s Gaucherovom bolesti nizak, bolest se smatra „rijetkom” te se od 9. lipnja 2010.
What is the risk associated with Vpriv? 
Koji su rizici povezani s lijekom Vpriv?
The summary of the opinion of the Committee for Orphan Medicinal Products for Vpriv is available on the Agency's website under EMA website/Find medicine/Human medicines/Rare disease designations. 
Sažetak mišljenja Odbora za lijekove za rijetke bolesti za lijek Vpriv nalazi se na internetskim stranicama Agencije: EMA website/Find medicine/Human medicines/Rare disease designations.
Vpriv is a medicine that contains the active substance velaglucerase alfa. 
Vpriv je lijek koji sadrži djelatnu tvar velaglucerazu alfa.
The study also showed that Vpriv is as effective as imiglucerase in controlling other signs of Gaucher disease. 
Istraživanje je također pokazalo da je Vpriv učinkovit koliko i imigluceraza u suzbijanju drugih znakova Gaucherove bolesti.
Gaucher disease occurs because of the lack of an enzyme called glucocerebrosidase. 
Do Gaucherove bolesti dolazi zbog nedostatka enzima nazvanog glukocerebrozidaza.
What is Vpriv? 
Što je Vpriv?
What is Vpriv used for? 
Za što se Vpriv koristi?
For more information about treatment with Vpriv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Vpriv pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Vpriv is used for the long-term treatment of patients with Gaucher disease. 
Vpriv se koristi za dugotrajno liječenje bolesnika s Gaucherovom bolesti.
Vpriv is used in patients who have type 1 Gaucher disease, the type that usually affects the liver, spleen and bones. 
Vpriv se primjenjuje u bolesnika koji boluju od Gaucherove bolesti tipa 1, tipa bolesti koja obično utječe na jetru, slezenu i kosti.
Vpriv treatment should be supervised by a doctor experienced in managing patients with Gaucher disease. 
Liječenje lijekom Vpriv treba nadgledati liječnik s iskustvom u liječenju Gaucherove bolesti.
Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called glucocerebrosidase, which normally breaks down a fat called glucocerebroside. 
Ljudi s Gaucherovom bolesti, rijetkim nasljednim poremećajem, nemaju dovoljno enzima nazvanog glukocerebrozidaza, koji inače razgrađuje masnoću nazvanu glukocerebrozid.
The CHMP decided that Vpriv's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za lijekove za humanu uporabu (CHMP) odlučio je da koristi od lijeka Vpriv nadmašuju s njim povezane rizike te je za njega preporučio izdavanje odobrenja za stavljanje u promet.
How does Vpriv work? 
Kako Vpriv djeluje?
How is Vpriv used? 
Kako se Vpriv koristi?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vpriv have also been included in the summary of product characteristics and the package leaflet. 
U sažetku opisa svojstava lijeka i uputi o lijeku također se nalaze preporuke i mjere opreza za sigurnu i učinkovitu primjenu lijeka Glubrava kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
What benefit has Vpriv shown during the studies? 
Koje su koristi lijeka Vpriv utvrđene u ispitivanjima?
How has Vpriv been studied? 
Kako je Vpriv ispitivan?
During pregnancy: 
Tijekom trudnoće:
Children and adolescents Ontruzant is not recommended for anyone under the age of 18 years. 
Ontruzant se ne preporučuje osobama mlađima od 18 godina.
If this happens to you, contact your doctor immediately. 
Ako Vam se to dogodi, odmah se obratite liječniku.
Unopened vials: 4 years. 
Neotvorene bočice: 4 godine
Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment. 
Stoga će Vam liječnik možda odlučiti nastaviti kontrolirati srčanu funkciju čak i nakon završetka liječenja.
This could be more serious if you are already breathless. 
Problemi mogu biti još ozbiljniji ako već osjećate nedostatka zraka.
Some of these symptoms can be serious and some patients have died (see section 2 under “Warnings and precautions”). 
Neki od ovih simptoma mogu biti ozbiljni, a neki su bolesnici preminuli (pogledajte dio 2 pod "Upozorenja i mjere opreza").
Other medicines and Ontruzant 
Drugi lijekovi i Ontruzant
Before starting the treatment your doctor will determine the amount of HER2 in your tumour. 
Prije početka liječenja liječnik će Vam odrediti razinu HER2 u tumoru.
Study M77001: Full analysis set (intent-to-treat), 24 months results 
Ispitivanje M77001: potpuni skup analiza (bolesnici predviđeni za liječenje), rezultati nakon 24 mjeseca
Monoclonal antibodies attach to specific proteins or antigens. 
Monoklonska protutijela vežu se za specifične proteine ili antigene.
Ontruzant can cause breathing difficulties, especially when it is first given. 
Ontruzant može izazvati poteškoće u disanju, osobito prilikom prve primjene.
• anaphylactic reactions (serious allergic reaction) 
• anafilaktičke reakcije (ozbiljna alergijska reakcija)
• Your doctor will advise you of the risks and benefits of taking Ontruzant during pregnancy. 
• Liječnik će Vam objasniti rizike i koristi primjene lijeka Ontruzant tijekom trudnoće.
If diluted aseptically, it may be stored for 24 hours (do not store above 30°C). 
Ako je razrijeđena u aseptičkim uvjetima, može se čuvati 24 sata (ne čuvati na temperaturi iznad 30°C).
What Ontruzant looks like and contents of the pack 
Kako Ontruzant izgleda i sadržaj pakiranja
The presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age. 
Prisutnost trastuzumaba u serumu majmunčadi nije bila povezana sa štetnim učincima na rast i razvoj od rođenja do 1 mjeseca života.
These events may occur as part of an infusion-related reaction or with a delayed onset. 
Ti se događaji mogu pojaviti kao dio reakcije povezane s infuzijom ili s odgođenim nastupom.
Ontruzant may also be given once a week for metastatic breast cancer. 
Ontruzant se također može davati jednom tjedno za metastatski rak dojke.
Contents of the pack and other information What Ontruzant contains 
Sadržaj pakiranja i druge informacije Što Ontruzant sadrži
The t1/2 decreases with decreasing concentrations within a dosing interval (see Table 16). 
Poluvijek (t1/2) smanjuje se s padom koncentracija unutar jednog intervala doziranja (vidjeti tablicu 16).
Ontruzant is given as an infusion into a vein (intravenous infusion, “drip”). 
Ontruzant se primjenjuje infuzijom izravno u venu (intravenska infuzija, „drip“).
Ontruzant may affect your ability to drive a car or operate machines. 
Ontruzant može utjecati na sposobnost upravljanja vozilima ili rada sa strojevima.
Some of these side effects may be serious and may lead to hospitalisation. 
Neke od tih nuspojava mogu biti ozbiljne i zahtijevati bolničko liječenje.
HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. 
HER2 se u velikim količinama nalazi na površini nekih stanica raka te potiče njihov rast.
The dose of Ontruzant depends on your body weight. 
Potrebna doza lijeka Ontruzant ovisi o Vašoj tjelesnoj težini.
AUC0-21days 
AUC0-21 dan
If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Ontruzant treatment. 
Ako se pojave znakovi zatajenja srca (srce nedostatno pumpa krv), možda ćete srčanu funkciju kontrolirati češće (svakih šest do osam tjedana), a možda ćete primati terapiju za zatajenje srca ili ćete morati prekinuti liječenje lijekom Ontruzant.
The product is not intended to be stored after reconstitution and dilution unless this has taken place under controlled and validated aseptic conditions. 
Čuvanje lijeka nakon rekonstitucije i razrjeđivanja nije predviđeno, osim ako je ono obavljeno u kontroliranim i validiranim aseptičkim uvjetima.
If you stop using Ontruzant 
Ako prestanete primati Ontruzant
Do not stop using this medicine without talking to your doctor first. 
Nemojte prestati primati Ontruzant ako o tome prethodno niste razgovarali sa svojim liječnikom.
The efficacy results from the BCIRG 006 are summarized in Tables 9 and 10. 
Rezultati djelotvornosti iz ispitivanja BCIRG 006 sažeto su prikazani u tablicama 9 i 10.
If you receive Ontruzant in combination with chemotherapy, some of them may also be due to the chemotherapy. 
Ako primate Ontruzant u kombinaciji s kemoterapijom, neke od njih mogu biti i posljedica primljene kemoterapije.
AUCss, 0-21 days 
AUCss, 0-21 dan
Caution should be exercised for pneumonitis, especially in patients being treated concomitantly with taxanes. 
Potreban je oprez u slučaju pneumonitisa, osobito u bolesnika koji istodobno primaju taksane.
Observation N=1697*** 
Opservacija N=1697***
1 Denotes adverse reactions that are reported largely in association with Infusion-related reactions. 
1 Označava nuspojave koje su uglavnom prijavljivane u vezi s reakcijama povezanima s infuzijom.
If a pregnant woman is treated with trastuzumab, or if a patient becomes pregnant while receiving trastuzumab or within 7 months following the last dose of trastuzumab, close monitoring by a multidisciplinary team is desirable. 
Ako se trudnicu liječi trastuzumabom ili ako bolesnica zatrudni tijekom liječenja trastuzumabom ili unutar 7 mjeseci nakon posljednje doze trastuzumaba, poželjno je pažljivo multidisciplinarno praćenje.